This conference is organised by Elsevier.
Abstract submission deadline - October 19, 2018
Early Bird Registration Deadline - January 11, 2019
Philip T. LoVerde
Department of Pathology, University of Texas, San Antonio, USA
Dr. Philip T. LoVerde is a Professor at the University of Texas Health Science Center in San Antonio, Texas. His research interests are in host-parasite interactions, especially those that involve the human blood fluke, Schistosoma.
View full bio
His current research involves vaccine development, role of signal transduction in schistosome-host interactions, interplay between male and female parasites that results in female reproductive development, role of host genes in infection outcomes, genomics and genetic approach to identifying drug resistant genes. He serves as Editor and on the editorial boards of 10 journals. He has a history of service as a consultant for the National Institutes of Health, US AID, the World Health Organization and the Wellcome Trust. He has received a number of honors such as Distinguished Professor at the State University of New York. He has published over a 180 papers.
Molecular Parasitology, New York Blood Center, New York, USA
Dr. Sara Lustigman is the Head of the Laboratory of Molecular Parasitology at Lindsley F. Kimball Research Institute of the New York Blood Center. Her research over the past 25 years has focused on finding novel means to support the prevention of onchocerciasis, also known as river blindness, and lymphatic filariasis, also known as elephantiasis.
View full bio
To achieve this she has been studying the biology of Onchocerca volvulus and Brugia malayi, the causative agents of these diseases. Information gained by studying the basic biology and host-parasite interactions has allowed the identification of key pathways and molecules that are essential for parasite development, propagation and /or survival. While many aspects of her research are basic, her ultimate goal is to identify new strategies by which humans can be protected from these parasitic infections by either chemotherapeutic (drugs) or immunological (vaccines) means.
Jeff Bethony, George Washington University, USA
Elodie Ghedin, New York University, USA
Ray Pierce, Institut Pasteur de Lille, France
Judy Sakanari, UCSF, USA
Barton Slatko, New England Biolabs, USA